



Montclair State University

Environmental Health and Safety

Voice 973-655-4367
Fax 973-655-7837
E-mail ferdinanda@mail.montclair.edu

February 12, 2009

B-2

Ms. Betsy Ullrich
US Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, PA 19406 – 1415

Re License No: 29-03351-01

03037411

RECEIVED
REGION I
2009 FEB 25 PM 12: 28

Dear Ms. Ullrich

I respectfully request the following changes to the Montclair State University license

1. Please remove Dr. K. Lustigman (recently deceased) from the license
2. We are requesting the addition of Dr. John Siekierka to our license; his research includes the use of micro amounts of P-32. Dr. Siekierka, the former director of research and development at Johnson & Johnson's Center for Biomaterials and Advanced Technologies is the director of the newly-created Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences and Sokol Professor of Medicinal Chemistry. With over 20 years devoted to managing research and investigators involved in biochemical, immunological and drug discovery research, Dr. Siekierka has extensive hands-on experience in pharmaceutical research and in-depth knowledge of the industry. Prior to his position as director of research and development at Johnson & Johnson, he was senior research fellow at Johnson & Johnson Pharmaceutical Research and Development, L.L.C. and prior to that, was director of the Department of Molecular Immunology at the Johnson & Johnson Immunobiology Research Institute. He has also held senior research positions at Merck Research Laboratories and the Roche Institute of Molecular Biology.

Please let me know if you have any questions or require additional information

Respectfully


Amy N. Ferdinand

143462

Curriculum Vitae
John J. Siekierka
Sokol Professor of Medicinal Chemistry and
Director of the Sokol Institute of Pharmaceutical Life Sciences
Montclair State University
Montclair, New Jersey 07043

Office Phone: 973-655-3411
Mobile Phone: 973-214-1338
E-mail: siekierkaj@mail.montclair.edu

Education: Seton Hall University, South Orange, NJ, B.S., Chemistry, 1971
City University of New York, N.Y., NY, M.S., Chemistry, 1974
New York University, NY, NY, Ph.D., Biochemistry, 1982

Professional Appointments:

8 /2007 – present	Montclair State University Department of Chemistry & Biochemistry Professor of Medicinal Chemistry & Director , Sokol Institute of Pharmaceutical Life Sciences
2006 – 8/2007	Johnson & Johnson Center for Biomaterials and Advanced Technologies Director, Research and Development
1994 – 2007	University of Medicine and Dentistry Department of Molecular Genetics and Molecular Biology Adjunct Faculty Member
1995 – 2006	Johnson & Johnson J & J Pharmaceutical Research & Development Senior Research Fellow, Head, Immunology
1992 – 1995	Johnson & Johnson Immunobiology Research Institute Director, Department of Molecular Immunology

1985 – 1992	Merck Research Laboratories Senior Research Fellow Department of Immunology Research
1981 – 1985	The Roche Institute of Molecular Biology Senior Scientist, Department of Biochemistry
1976 – 1981	Hoffmann LaRoche, Inc. & NYU Predoctoral Fellow Mentor: Dr. Severo Ochoa
1971 – 1976	Hoffmann LaRoche, Inc. Assistant Scientist II

Professional Experience & Skills

- Professor of Medicinal Chemistry at Montclair State University teaching undergraduate and graduate students.
- Founding Director of the Sokol Institute of Pharmaceutical Life Sciences at Montclair State University.
- Academic research programs in HIV and parasitic diseases and drug discovery technology. Mentor both undergraduate and graduate student research.
- Over 20 years experience managing research and investigators involved in Biochemical, Immunological and Drug Discovery research.
- Have an extensive background in Biochemistry, Immunology, Pharmacology and Drug Discovery Research.
- Maintain strong collaborative research ties with several academic investigators at UMDNJ, University of Pennsylvania, Johns Hopkins University and the San Antonio Cancer Institute.
- Consistent publication record on original research.
- Have trained post-doctoral fellows and summer students in my laboratories at Merck and Johnson & Johnson.

Key Scientific Accomplishments & Contributions

- Elucidated the mechanism whereby phosphorylation of protein synthesis initiation eIF-2 leads to cessation of protein synthesis by interfering with GDP/GTP exchange. Critical regulatory mechanism in eukaryotic cells and in viral protein synthesis.
- First to isolate, clone and patent the receptor for the immunosuppressive agents FK-506 and rapamycin.
- Elucidated the mechanism of action of the immunosuppressant agent rapamycin. Demonstrated that rapamycin uniquely inhibits G1-S progression during the cell cycle.

- Established a program aimed at developing small molecule inhibitors of p38 MAP Kinase. Developed and progressed JNJ 67657 into clinical trials.
- Identified the role of p38 MAP kinase in toxoplasmosis infection, HIV infection and in epithelial-mesenchymal transition (EMT).
- Co-developed the rapamycin-eluting coronary stent. Directed the pharmacological & biochemical aspects of the program. Successfully led to the launch of the Cypher drug-eluting stent. Awarded the Johnson Medal, J & J's highest award for scientific research and development.

Student Research History:

January, 2008 - Present - Katie Gaskill CHEM 199/CHEM 499, Laboratory Project, Montclair State University.

January, 2008 - Present - Nalinai Panther CHEM499, Undergraduate Research, Montclair State University.

July, 2008 - Present - Sailaja Sankabathula Graduate Assistant & Graduate Thesis Research, Montclair State University.

September, 2008 - Mouhanad Bittar, Non-thesis literature search project.

2005 - 2007 - Dr. Ingrid Sprintz, Postdoctoral Fellow, Johnson & Johnson.

2005 - 2006 - Dr. Lin Lin, Postdoctoral Fellow, Johnson & Johnson.

2003 - 2004 - Dr. Hirndra Abeysinghe, Postdoctoral Fellow, Johnson & Johnson.

2003 - 2005 - Dr. Steven Lang, Postdoctoral Fellow, Johnson & Johnson.

1999 - 2000 - Dr. Liwein Wang, Postdoctoral Fellow, Johnson & Johnson.

1998- 2000 - Dr. Peter Schafer, Postdoctoral Fellow, Johnson & Johnson.

Ad Hoc Journal Reviewer

Journal of Immunology
Journal of Biological Chemistry
Editor, Methods, Vol 9, (2) 1996.

Professional Societies:

Association for the Advancement of Science
American Society for Biochemistry and Molecular Biology
International AIDS Society Member

Awards & Honors

Awarded the Hoffman LaRoche, Pre-Doctoral Research Fellowship, 1976-1981.

Awarded the RW Johnson Excellence in Science Award for the development of novel p38 MAP kinase inhibitors, 1995.

J & J Excellence in Science Awards, 1996 & 2001.

The Johnson and Johnson Corporate Standards in Leadership Award for "Collaboration in the Development of the Rapamycin-Coated Coronary Stent, 2001.

Awarded The Johnson Medal for "The Discovery and Development of the Cypher™ Drug-Eluting Stent", 2003.

Issued Patents (11 additional filed):

1. U.S. Patent No. 5109112. **Siekierka, J.J.**, Hung, H-Y, Staruch, M.J., Sigal, N.H. and Murnford, R. FK-506 Cytosolic Binding Protein. Issue date, 4/28/1992.
2. U.S. Patent No. 5196352. **Siekierka, J.J.**, Hung, H-Y, Staruch, M.J., Sigal, N.H. and Mumford, R. New FK-506 Cytosolic Binding Protein. Issue date, 3/23/1993.
3. U.S. Patent No. 5472856. Harris, C.A., Goldstein, G., **Siekierka, J.J.**, Talle, M.A., Shenbagamurthi, P., Culler, M.D. and Setcavage, D.R. Recombinant Human Thymopoeitin and Uses Thereof: Issue date, 12/5/1995.
4. U.S. Patent No. 6166289. Harris, C.A., **Siekierka, J.J.**, Peterson, P.A. and Lung, W-P. IRAK Modified Transgenic Animals. Issue date, 12/26/2000.
5. U.S. Patent No. 6776796. Falotico, R., Kopia, G.A., Llanos, G.H., **Siekierka, J.**, and Carter, A.J. Antiinflammatory drug and delivery device. Issue date, 8/17/2004.

Publications:

1. McClain, R.M. and **Siekierka, J.** The effects of various chelating agents on the teratogenicity of lead nitrate in rats. *Tox. And Appl. Pharm.* **31:434**, 1975.
2. McClain, R.M. and **Siekierka, J.** The placental transfer of lead-chelate complexes in the rat. *Tox. and Appl. Pharm.* **31:443**, 1975.

3. **Siekierka, J.**, Mitsui, K.I., and Ochoa, S. Mode of action of the heme-controlled translational inhibitor: Relationship of eukaryotic initiation factor 2-stimulating protein to translation restoring factor. *Proc. Natl. Acad. Sci.* **78**:220, 1981.
4. Ochoa, S., de Haro, C., **Siekierka, J.**, Grosfeld, H. Role of phosphorylation-dephosphorylation cycles in the control of protein synthesis in eukaryotes. *Curr. Topics. Cell. Reg.* **18**:421, 1981.
5. Ochoa, S., **Siekierka, J.**, Mitsui, K., de Haro, C., and Grosfeld, H. Protein phosphorylation and translational control. *Eight Cold Spring Harbor Conference on Cell Proliferation*. Rosen, O.M. and Krebs, E.G. eds. **8**:931, 1981.
6. **Siekierka, J.**, and Ochoa, S. Mechanism of translational inhibition associated with phosphorylation of the alpha subunit of eukaryotic initiation factor-2. *The Regulation of Hemoglobin Biosynthesis*. Goldwasser, E. ed. Elsevier Biomedical, New York, p. 253, 1983.
7. **Siekierka, J.**, Mauser, L., and Ochoa, S. Mechanism of polypeptide chain initiation in eukaryotes and its control by phosphorylation of the alpha subunit of initiation factor -2. *Proc. Natl. Sci. USA.* **79**:2537, 1982.
8. **Siekierka, J.**, Datta, A., Mauser, L., and Ochoa, S. Initiation of protein synthesis in eukaryotes: Nature of ternary complex dissociation factor. *J. Biol. Chem.* **257**:4162, 1982.
9. **Siekierka, J.**, Mauser, L., and Ochoa, S. The control of polypeptide chain initiation by phosphorylation of the alpha subunit of the initiation factor eIF-2. *Developments in Biochemistry: Interaction of Translational and Transcriptional Controls in the Regulation of Gene Expression*. Grunberg-Manago, M., and Safer, B. eds. **24**:327, 1982.
10. Siekierka, J., Manne, V., Mauser, L., and Ochoa, S. Polypeptide chain initiation in eukaryotes: reversibility of the ternary complex-forming reaction. *Proc. Natl. Sci. USA.* **80**:1232, 1983.
11. **Siekierka, J.J.**, Manne, V., and Ochoa, S. Mechanism of translational control by partial phosphorylation of the alpha subunit of eukaryotic initiation factor 2. *Proc. Natl. Sci. USA.* **81**:352, 1984.
12. Rosen, C.A., Siekierka, J.J., Ennis, H.L., and Cohen, P.S. Inhibition of protein synthesis in vesicular stomatitis virus-infected Chinese hamster ovary cells: role of virus mRNA-ribonucleoprotein particle. *Biochemistry.* **23**:2407, 1984.

13. Reichel, P.A., Merrick, W.C., **Siekierka, J.**, and Mathews, M.B. Regulation of protein synthesis initiation factor by adenovirus-associated RNA. *Nature*. 313:196,1985.
14. **Siekierka, J.**, Mariano, T.M., Reichel, P.A., and Mathews, M.B. Translational control by adenovirus: Lack of virus-associated RNAI during adenovirus infection results in phosphorylation of initiation factor eIF-2 and inhibition of protein synthesis. *Proc. Natl. Sci. USA*. 82:1959, 1985.
15. **Siekierka, J.**, Mariano, T.M., Ochoa, S., Reichel, P., and Mathews, M.B. The role of guanine nucleotides in translational control by protein phosphorylation. *Biochem. Soc. Trans.* 13:671, 1985.
16. O'Malley, R.P., Mariano, T.M., **Siekierka, J.**, and Mathews, M.B. A mechanism for the control of protein synthesis by adenovirus VA RNAI. *Cell*. 44:391, 1986.
17. Mariano, T.M., **Siekierka, J.**, and Ochoa, S. Purification and properties of the guanine nucleotide exchange factor (GEF) from HeLa cells and its role in the initiation of protein synthesis. *Biochem. Biophys. Res. Comm.* 134:1160, 1986.
18. Mariano, T.M. and **Siekierka, J.** Inhibition of HeLa cell protein synthesis under heat shock conditions in the absence of initiation factor eIF-2 alpha phosphorylation. *Biochem. Biophys. Res. Comm.* 138:519, 1986.
19. O'Malley, R.P., Mariano, T.M., **Siekierka, J.**, Merrick, W.C., Reicher, P.A. and Mathews, M.B. The control of protein synthesis by adenovirus VA RNA. *Cancer Cells, Vol 4, DNA Tumor Viruses: Control of Gene Expression and Replication*, pp. 291-301.
20. **Siekierka, J.** and DeGudicibus, S. Radioiodination of interleukin2 to high specific activities by the vapor-phase chloramines T method. *Anal. Biochem.* 172:514, 1988.
21. Tocci, M.J., Matkovich, D.A., Collier, K.A., Kwok, P., Durnont, F., Lin, S., Degudicibus, S., **Siekierka, J.J.**, Chin, J., and Hutchinson, N.I. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. *J. Immunol.* 143:718, 1989.
22. **Siekierka, J.J.**, Staruch, M.J., Hung, S.H., and Sigal, N.H. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporine A-binding protein, cyclophilin. *J. Immunol.* 143:1580, 1989.

23. **Siekierka, J.J.**, Hung, S.H., Poe, M., Lin, C.S., and Sigal, N.H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. *Nature*. **341**:755, 1989.
24. Sigal, N.H., **Siekierka, J.J.**, and Dumont, F.J. Observations on the mechanism of action of FK-506, a pharmacological probe of lymphocyte signal transduction. *Biochem. Pharm.* **40**:2201, 1990.
25. **Siekierka, J.J.**, Wiederrecht, G., Greulich, H., Boulton, D., Hung, S.H., Cryan, J., Hodges, P.J. and Sigal, N.H. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. *J. Biol. Chem.* **265**:21011, 1990.
26. Wiederrecht, G., Brizuela, L., Elliston, K., Sigal, N.H. and **Siekierka, J.J.** FKB1 encodes a nonessential FK-506-binding protein in *Saccharomyces cerevisiae* and contains regions suggesting homology to the cyclophilins. *Proc. Natl. Acad. Sci. USA.* **88**:1029, 1991.
27. Sigal, N.H., Dumont, F., Durette, P., **Siekierka, J.J.**, Peterson, L., Rich, D.H., Dunlap, B.E., Staruch, M.J., Melino, M.R., and Koprak, S.L. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporine A? *J. Expl. Med.* **173**:619, 1991.
28. Lin, C.S., Boltz, R.C., **Siekierka, J.J.**, and Sigal, N.H. FK-506 and cyclosporine A inhibit highly similar signal transduction pathways in human T lymphocytes. *J. Cell. Immun.* **133**:269, 1991.
29. Sigal, N.H., Lin, C.S., and **Siekierka, J.J.** Inhibition of human T-cell activation by FK-506, rapamycin and cyclosporine A. *Trans. Proc.* **23**:1, 1991.
30. Cryan, J., Hung, S.H., Wiederrecht, G., Sigal, N.H. and **Siekierka, J.J.** FKPB, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. *Biochem. Biophys. Res. Comm.* **180**:846, 1991.
31. **Siekierka, J.J.**, Wiederrecht, G., Cryan, J., Hung, S.H., Comisky, M. and Sigal, N.H. Potential roles of other FK-506-binding proteins in mediating the effects of FK-506. *Trans. Proc.* **23**:2720, 1991.
32. Sigal, N.H., Dumont, F.J., **Siekierka, J.J.**, Wiederrecht, G., Parent, S.A. and Brizuela, L. Is FKBP involved in the immunosuppressive and / or toxic mechanisms of action of FK-506? *Trans. Proc.* **23**:2846, 1991.

33. Wiederrecht, G., Martin, M.M., Sigan, N.H., and **Siekierka, J.J.** Isolation of a human cDNA encoding a 25kDa FK-506 and rapamycin binding protein. *Biochem. Biophys. Res. Comm.* **185**:298, 1992.
34. Nielsen, J.B., Foor, F., **Siekierka, J.J.**, Hsu, M. J., Ramadan, N., Morin, N., Shafiee, A., Dahl, A.M., Brizuela, L. and Chrebet, G. Yeast FKBP-13 is a membrane-associated FK-506-binding protein encoded by the nonessential gene FKB2. *Proc. Natl. Acad. Sci. USA.* **89**:7471, 1992.
35. Dumont, F.J., Staruch, M.J., Koprak, S.L., **Siekierka, J.J.**, Lin, C.S., Harrison, R., Sewell, T., Kindt, V.M., Beattie, T.R. and Wyvratt, M. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. *J. Expl. Med.* **176**:751, 1992.
36. Wiederrecht, G., Hung, S., Chan, H.K., Marcy, A., Martin, M., Calaycay, J., Boulton, D., Sigal, N.H., Kincaid, R.L., and **Siekierka, J.J.** Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. *J. Biol. Chem.* **267**:21753, 1992.
37. **Siekierka, J.J.** and Sigal, N.H. FK-506 and cyclosporine A: immunosuppressive mechanism of action and beyond. *Curr. Opin. Immunol.* **4**:548, 1992.
38. Morice, W.G., Brunn, G.J., Wiederrecht, G., **Siekierka, J.J.**, and Abraham, R.T. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. *J. Biol. Chem.* **268**:3734, 1993.
39. Morice, W.G., Wiederrecht, G., Brunn, G.J., **Siekierka, J.J.**, and Abraham, R.T. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. *J. Biol. Chem.* **268**:22737, 1993.
40. Harris, C.A., Andryuk, P.J., Cline, S., Chan, H.K., Natarajan, A., **Siekierka, J.J.**, and Goldstein, G. Three distinct thymopoietins are derived from alternatively spliced mRNAs. *Proc. Natl. Sci. USA.* **91**:6283, 1994.
41. **Siekierka, J.J.** Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin. *Immun. Res.* **13**:110, 1994.
42. Goulet, M.T., Hodkey, D.W., Staruch, M.J., Dumont, F.J., Lin, S., Hung, S.Y., **Siekierka, J.J.**, Wyvratt, M.J. Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-0-desmethyl ascomycin). *Bioorg. Med. Chem. Lett.* **4**:927, 1994.

43. Harris, C.A., Andryuk, P.J., Cline, S.W., Mathew, S., **Siekierka, J.J.** and Goldstein, G. Structure and mapping of the human thymopoietin (TMPO) gene and relationship of human TMOP beta to rat lamin-associated polypeptide 2. *Genomics*. 28:198, 1995.
44. Beers, S.A., Malloy, E.A., Wu, W., Wachter, M.P., Gunnia, U., Cavender, D., Harris, C. Davis, J. Brosius, K., Pellegrino-Gensey, L. and **Siekierka, J.J.** Nitroarylhydroxymethylphosphonicacids as inhibitors of CD45. *Bioorg. Med. Chem.* 5:2203, 1997.
45. **Siekierka, J.J.** Mammalian FKBP12. *Guidebook to molecular chaperones and protein folding catalysts*. Pp. 420-421, 1997.
46. Wiederrecht, G. and **Siekierka, J.J.** Yeast immunophilins: purification and assay of yeast FKBP12. *Meth. Enzymol.* 290:74, 1998.
47. Kanakaraj, P., Schafer, P.H., Cavender, D.E., Wu, Y., Ngo, K., Grealish, P.F., Wadsworth, S. A., Peterson, P.A., **Siekierka, J.J.**, Haris, C.A., and Fung-Leung, W.P. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. *J. Expl. Med.* 187:2073, 1998.
48. Dechat, T., Gotzmann, J., Stockinger, A., Harris, C.A., Talle, M.A., **Siekierka, J.J.**, and Foisner, R. Detergent-salt resistance of LAP2 alpha in interphase nuclei and phosphorylation-dependent association with chromosomes early in nuclear assembly implies functions in nuclear structure dynamics. *EMBO. J.* 17:4887, 1998.
49. Henry, J.R., Rupert, K.C., Dodd, J.H., Turchi, I.J., Wadsworth, S.A., Cavender, D.E., Fahmy, B., Olini, G.C., Davis, J.E., Pellegrino-Gensey, L., Schafer, P.H. and **Siekierka, J.J.** 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. *J. Med. Chem.* 41:4196, 1998.
50. Bullington, J.L., Cameron, J.C., Davis, J.E., Dodd, J.H., Harris, C.A., Henty, J.R., Pellegrino-Gensey, L., Rupert, K.C., and **Siekierka, J.J.** The development of novel and selective p56 lck tyrosine kinase inhibitors. *Bioorg. Med. Chem. Lett.* 8:2489, 1998.
51. Henry, J.R., Rupert, K.C., Dodd, J.H., Turchi, I.J., Wadsworth, S.A., Cavender, D.E., Schafer, P.H. and **Siekierka, J.J.** Potent inhibitors of the MAP kinase p38. *Bioorg. Med. Chem. Lett.* 8:3335, 1998.

52. Schafer, P.H., Wang, L., Wadsworth, S.A., Davis, J.E., and **Siekierka, J.J.** T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. *J. Immunol.* **162**:659, 1999.
53. Kanakaraj, P., Ngo, K., Wu, Y., Angulo, A., Ghazal, P., Harris, C.A., **Siekierka, J.J.**, Peterson, P.A., and Fung-Leung, W.P. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. *J. Expl. Med.* 189:1129, 1999.
54. Schafer, P.H., Wadsworth, S.A., Wang, L., and **Siekierka, J.J.** p38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. *J. Immunol.* **162**:7110, 1999.
55. Wadsworth, S.A., Cavender, D.E., Beers, S.A., Lalan, P., Schafer, P.H., Malloy, E.A., Wu, Y., Fahmy, B., Olini, G.C., Davis, J.E., Pelligrino-Gensey, J.L., Wachter, M.P. and **Siekierka, J.J.** RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. *J. Pharm. Expl. Therap.* **291**:680, 1999.
56. Thurmond, R.L., Wadsworth, S.A., Schafer, P.H., Zivin, R.A. and **Siekierka, J.J.** Kinetics of small molecule inhibitor binding to p38 kinase. *Euro. J. Biochem.* **268**:5747, 2001.
57. Tao, L., Wadsworth, S.A., Mercer, J., Mueller, C., Lynn, K., **Siekierka, J.J.**, and August, A. Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells. *Biochem. J.* 363:175, 2002.
58. Rupert, K.C., Henry, J.R., Dodd, J.H., Wadsworth, S.A., Cavender, D.E., Olini, G.C., Fahmy, B., and **Siekierka, J.J.** Imidazopyrimidines, potent inhibitors of p38 MAP kinase. *Bioorg. Med. Chem. Lett.* **13**:347, 2003.
59. Muthumani, K., Wadsworth, S.A., Dayes, N.S., Hwang, D.S., Choo, A.Y., Abeysinghe, H.R., **Siekierka, J.J.**, and Weiner, D.B. Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. *AIDS.* **18**:739, 2004
60. Birge, R.B., Wadsworth, S.A., Akakura, R., Abeysinghe, H., Kanojia, R., Maclellag, M., Desbarats, J., Escalante, M., Singh, K., Sundarababu, S., Parris, K., Childs, G., August, A., **Siekierka, J.J.**, and Weinstein, D.E. A role for Schwann cells in the neuroregenerative effects of a non-immunosuppressive FK 506 derivative, JNJ 460. *Neuroscience.* **124**:351, 2004.

61. Sanokawa-Akakura, R., Dai, H., Akakura, S., Weinstein, D., Fajardo, J.E., Lang, S.E., Wadsworth, S.A., **Siekierka, J.J.**, and Birge, R.B. A novel role for the immunophilin FKBP52 in copper transport. *J. Biol. Chem.* **279**:27845, 2004.
62. Muthumani, K., Choo, A.Y., Hwang, D.S., Premkumar, A., Dayes, N.S., Harris, C. Green, D.R., Wadsworth, S.A., **Siekierka, J.J.**, and Weiner, D.B. HIV Nef-induced FasL induction and bystander killing requires p38 MAPK activation. *Blood.* **106**:2059, 2005.
63. Parry, T.J., Brosius, R., Thyagarajan, R., Carter, D., Argentieri, D., Falotico, R., and **Siekierka, J.J.** Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. *Eur. J. Pharm.* **524**:19, 2005.
64. Parry, T.J., Thyagarajan, R., Argentieri, D., Falotico, R., **Siekierka, J.J.**, and Tallarida, R.J. Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis. *Eur. J. Pharm.* **532**:38, 2006.
65. Liu, T., D'Mello, V., Deng, L., Hu, J., Ricardo, M., Pan., S., Lu, X., Wadsworth, S.A., **Siekierka, J.J.**, Rirge, R., and Hong, L. A multiplexed proteomics approach to differentiate neurite outgrowth patterns. *J. Neuro. Methods.* **158**:22, 2006.
66. Bullington, J., Argentieri, D., Averill, K., Carter, D., Cavender, D., Fahmy, B., Fan, X., hall, D., Heintzelman, G., Jackson, P., Leung, W-P., Li, X., Linh, P., Olini, G., Razler, T., Reuman, M., Rupert, K., Russell, R., **Siekierka, J.J.**, Wadsworth, S.A., Wolff, R., Xiang, B., and Zhang, Y-M. Inhibitors of unactivated p38 MAP kinase. *Bioorg. Med. Chem. Lett.* **16**:6102, 2006.
67. Wei, S., Daniel, B.J., Brumlik, M.J., Burow, M.E., Zou, W., Khan, I., Wadsworth, S., **Siekierka, J.** and Curiel, T.J. Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat *Toxoplasma gondii* and *Encephalitozoon cuniculi* infection. *Antimicrob. Agents Chemother.* **51**: 4324, 2007.
68. Petrilli, J., Wadsworth, S., Cooper, K., Rodgers, K.E., **Siekierka, J.**, and diZerega, G.S. Tranilast: A pharmaceutical candidate for reduction of adhesions using a novel approach. *Seminars in Repro. Med.* **26**: 341-348, 2008.

Invited Speaker (selective list from 1990 external to J & J)

1. New York Academy of Sciences Conference on Immunosuppression, New York, N.Y. October 23, 1990. *The Biochemistry and Molecular Biology of the FK-506 Binding Protein.*
2. The First International Symposium on FK-506. Pittsburgh, PA. August 21-24, 1991. *FK-506 Binds to a Family of Cytosolic Receptors.*
3. Engineering Foundation Conference on Cell Culturing Engineering III: Regulation of Secretory Protein Synthesis, Post-Translational Processing and Secretion. Palm Coast, FL. February 2-7, 1992. *Peptidyl-Prolyl cis-trans Isomerases: Biochemistry and Role in T-cell Signal Transduction and Immunosuppression.*
4. Symposium on Molecular Aspects of Rheumatic Diseases. University of Pennsylvania School of Medicine, Philadelphia, PA. June 9-10. *Probing T-cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin.*
5. Massachusetts Institute of technology, Cambridge, MA. November 20, 1996. *Drug Discovery: Protein Kinase and Phosphatase Inhibitors as Signal Transduction Probes.*
6. Mount Sinai School of Medicine, N.Y., N.Y. December 20, 1996. *Protein Kinases and Phosphatase Inhibitors as Signal Transduction Probes.*
7. Advances in Targeted Therapies. Miami Beach, FL. March 29, 2000. *Small Molecule Inhibitors of p38 MAP Kinase: Potential Novel Therapeutic Applications.*
8. Conquering Airway Inflammation in the 21st Century. Imperial College School of Medicine, London, UK. September 11, 2000. *Role of p38 MAP Kinase in TH2-Mediated Allergic Responses.*
9. Duke University School of Medicine. April 13, 2001 *The Use of Small Molecule Inhibitors of p38 MAP Kinase as Signal Transduction Probes.*
10. Symposium: Protein Kinases in Drug Discovery and Development. Newark, NJ. October 16, 2001. *The Use of Small Molecule Inhibitors of p38 MAP Kinase as Signal Transduction Probes.*
11. Symposium: Protein Kinases. San Diego, CA. March 6-8. *Novel Therapeutic uses for Small Molecule Inhibitors of p38 MAP Kinase.*

12. Columbia University. March 2002. *The Use of Small Molecule Inhibitors of p38 MAP Kinase as Signal Transduction Probes.*
13. Symposium: Inflammation Research Association. Lake George, NY. October 6-10, 2003. *Small Molecule Inhibitors of p38 MAP Kinase.*
14. Princeton ACS Symposium. Princeton, NJ. July 2004. *Drug Device Technology: Development of the Cypher™ Drug-Eluting Stent.*
15. San Antonio Cancer Institute, January 24, 2008. *Emerging Technologies in the Pharmaceutical Industry: Drug /Device Combinations for the Treatment of Disease.*

This is to acknowledge the receipt of your letter/application dated

2/12/2009, and to inform you that the initial processing which includes an administrative review has been performed.

AMEND. 29-03351-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 143462.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (R1)
(6-96)

Sincerely,
Licensing Assistance Team Leader